The FDA has approved Intellia Therapeutics’ in vivo CRISPR therapy for hereditary angioedema (HAE), clearing lonvoguran ziclumeran (lonvo-z) for the one-dose genome-editing approach following a successful Phase 3 HAELO program. The approval follows publication of the trial’s results in the New England Journal of Medicine. For clinicians and patients in HAE, the key change is the move from recurring attack prevention therapies toward a potentially durable, single-administration treatment built around an mRNA-lipid nanoparticle platform. The BLA clearance is positioned as a meaningful shift in a disease defined by unpredictable, sometimes life-threatening swelling. The report highlights that lead investigator Danny Cohn of Amsterdam University Medical Center and clinical associates discussed the disease burden and the practical implications of attack unpredictability on daily life, travel, and work. Independent commentary from clinicians underscored safety and the clinical need for improved tolerability in HAE management. Overall, the approval adds to momentum for in vivo genome editing in non-oncology indications—an area where real-world usability, durability, and safety have to be demonstrated carefully.